These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 2572243)

  • 1. New perspectives on selective alpha 1 blockade.
    Luther RR
    Am J Hypertens; 1989 Sep; 2(9):729-35. PubMed ID: 2572243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in essential hypertension.
    Titmarsh S; Monk JP
    Drugs; 1987 May; 33(5):461-77. PubMed ID: 2885169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alpha 1-blockade for the treatment of hypertension: a megastudy of terazosin in 2214 clinical practice settings.
    Itskovitz HD
    Clin Ther; 1994; 16(3):490-504. PubMed ID: 7923316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Terazosin: a new antihypertensive agent with favorable effects on lipids.
    Luther RR
    Int J Clin Pharmacol Ther Toxicol; 1989 Jul; 27(7):313-9. PubMed ID: 2570758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Terazosin, a new selective alpha 1-adrenergic blocking agent. Results of long-term treatment in patients with essential hypertension.
    Luther RR; Glassman HN; Estep CB; Schmitz PJ; Horton JK; Jordan DC
    Am J Hypertens; 1988 Jul; 1(3 Pt 3):237S-240S. PubMed ID: 2901267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alpha 1 blockers. Safe, effective treatment for hypertension.
    Itskovitz HD
    Postgrad Med; 1991 Jun; 89(8):89-92, 95-8, 103-6, passim. PubMed ID: 1674822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cardiovascular effects of alpha-receptor blocking agents.
    Leren P
    J Hypertens Suppl; 1992 Jun; 10(3):S11-4; discussion S14-5. PubMed ID: 1353110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sympathetic nervous system and hypertension. Therapeutic perspectives.
    Weber MA
    Am J Hypertens; 1989 Mar; 2(3 Pt 2):147S-152S. PubMed ID: 2564278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alpha 1-blockers, their antihypertensive efficacy and effects on lipids and lipoprotein.
    Kincaid-Smith P
    J Hum Hypertens; 1989 Dec; 3 Suppl 2():75-83. PubMed ID: 2575178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alpha 1-adrenoreceptor blockade and the molecular basis of lipid metabolism alterations.
    Pool JL; Lenz ML; Taylor AA
    J Hum Hypertens; 1990 Oct; 4 Suppl 3():23-33. PubMed ID: 1979819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical pharmacology of selective alpha blockers. Hemodynamics and effects on lipid levels.
    Reid JL; Elliott HL; Vincent J; Meredith PA
    Am J Med; 1987 Jan; 82(1A):15-20. PubMed ID: 3799697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse effects of alpha 1-adrenergic blocking drugs.
    Carruthers SG
    Drug Saf; 1994 Jul; 11(1):12-20. PubMed ID: 7917078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Terazosin: a new alpha 1-blocker for the treatment of hypertension: a review of randomized, controlled clinical trials of once-daily administration as monotherapy.
    Luther RR; Glassman HN; Sperzel WD; Steinberg FJ; Horton JK; Jordan DC
    J Hypertens Suppl; 1986 Dec; 4(5):S494-7. PubMed ID: 2883273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alpha-adrenergic blockers: mechanism of action, blood pressure control, and effects of lipoprotein metabolism.
    Nash DT
    Clin Cardiol; 1990 Nov; 13(11):764-72. PubMed ID: 1980236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective alpha-1 inhibitors: first- or second-line antihypertensive agents?
    Lund-Johansen P; Hjermann I; Iversen BM; Thaulow E
    Cardiology; 1993; 83(3):150-9. PubMed ID: 7904230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Doxazosin: a new alpha 1-adrenergic antagonist.
    Babamoto KS; Hirokawa WT
    Clin Pharm; 1992 May; 11(5):415-27. PubMed ID: 1349855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of selective alpha 1 blockers in the therapy of hypertension.
    Kaplan NM
    Am J Med; 1986 May; 80(5B):100-4. PubMed ID: 2872800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alpha-1-adrenergic blockade and lipoprotein metabolism in essential hypertension.
    Ferrier C; Beretta-Piccoli C; Weidmann P; Mordasini R
    Clin Pharmacol Ther; 1986 Nov; 40(5):525-30. PubMed ID: 2876796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic changes during antihypertensive therapies.
    Krone W; Nägele H
    J Hum Hypertens; 1989 Dec; 3 Suppl 2():69-73; discussion 74. PubMed ID: 2575177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antihypertensive agents and cardiovascular risk factors.
    Fodor JG
    Clin Ther; 1986; 8(5):490-509. PubMed ID: 2876774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.